568-03-002 ISMRM Abstract

Assessment of Liver Metabolic Alterations in Metabolic Dysfunction-Associated Steatohepatitis Using Hyperpolarized 13C-MRSI

Primary: Contrast Mechanisms - Hyperpolarized MR (Non-Gas)

Secondary: Preclinical Animal & in vitro MR - Probes & Targets

568-03-002 · MR Biomarkers of Hepatic Steatosis, Fibrosis, and Liver Disease · Wednesday, 13 May, 1:40 PM–2:35 PM · Digital Posters Row I

Keywords: Hyperpolarized MR (Non-Gas) Metabolic imaging Steatohepatitis Dynamic nuclear polarization HP 13C-MRSI

Accepted

Abdelazim Elsayed Elhelaly ^1,2, Fuminori Hyodo^3,4,5, Hirohiko Imai^5,6, Yoshifumi Noda⁶, Hiroki Kato⁶, Masayuki Matsuo^1,5,6

¹Department of Radiology, Frontier Science for Imaging, Gifu University, Gifu, Japan

²Faculty of Veterinary Medicine, Suez Canal University, Ismailia, Egypt

³Department of Pharmacology, Graduate School of Medicine, Gifu University, Gifu, Japan

⁴Center for One Medicine Innovative Translational Research (COMIT), Gifu University, Gifu, Japan

⁵Innovation Research Center for Quantum Medicine, Gifu University, Gifu, Japan

⁶Department of Radiology, Gifu University, Gifu, Japan

Presenting Author: Abdelazim Elsayed Elhelaly

Synopsis

Motivation:

Goals:

Approach:

Results:

Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

References

1. Peng, C., Stewart, A G., Woodman, O L., Ritchie, R H., & Qin, C X. Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments. Frontiers Media, 2020;11. DOI: 10.3389/fphar.2020.603926 [doi]

2. Friedman, S L., Neuschwander‐Tetri, B A., Rinella, M E., & Sanyal, A J. Mechanisms of NAFLD development and therapeutic strategies. Nature Portfolio, 2018; 24(7), 908-922. DOI: 10.1038/s41591-018-0104-9 [doi]

3. Ardenkjær-Larsen, J H., Fridlund, B., Gram, A., Hansson, G., Hansson, L., Lerche, M H., Servin, R., Thaning, M., & Golman, K. . Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR. Natl. Acad. Sci. U.S.A. 2003;100 (18) 10158-10163. DOI: 10.1073/pnas.1733835100 [doi]

4. Harrison, S., Ratziu, V., Boursier, J., Francque, S., Bédossa, P., Majd, Z., Cordonnier, G., Sudrik, F B., Darteil, R., Liebe, R., Magnanensi, J., Hajji, Y., Brozek, J., Roudot, A., Staels, B., Hum, D W., Megnien, S., Hosmane, S., Dam, N., Sanyal, A J. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. Elsevier BV, 2020; 5(11), 970-985. DOI: 10.1016/S2468-1253(20)30252-1 [doi]

5. Piraquive Agudelo J, Kim Y, Agarwal S, et al. Hyperpolarized [1-13C] pyruvate MRSI to detect metabolic changes in liver in a methionine and choline-deficient diet rat model of fatty liver disease. Magn Reson Med. 2024; 91(4): 1625-1636. DOI: 10.1002/mrm.29954 [doi]

6. Nakata, R., Hyodo, F., Murata, M. et al. In vivo redox metabolic imaging of mitochondria assesses disease progression in non-alcoholic steatohepatitis. Sci Rep 2017; 7, 17170. DOI: 10.1038/s41598-017-17447-2 [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/568-03-002